By the end of this video, you'll be able to
describe how safety is measured during the
drug discovery phase. You will also be able to define a molecule's therapeutic index. The US FDA and other
regulatory agencies approve new molecules as
drugs based on their being safe and effective. Not only is safety important from a
regulatory standpoint, but safety can
also differentiate one drug from another
in clinical practice. All other things being equal, healthcare providers
and patients will favor a drug with
fewer adverse effects or lower toxicity when selecting between two drugs for
the same medication. The final safety profile
of a drug is based on the spectrum of adverse
effects observed in humans, along with the potential for toxicities to arise
at the approved dose, and at higher doses
or exposures. Doses of a drug
that are studied in humans are chosen to avoid toxicities that may arise at higher dose levels and
dosing is based on part, on pre-clinical safety studies. Therefore, drug-hunting
teams must be able to identify potential toxicities of an experimental compound, identify the dose or exposure
at which they may occur, and identify safe doses
to test in humans. The task of evaluating
safety begins even as early as the
lead selection stage. At this stage, the
efficacy of a molecule is typically measured as
activity against the target, either through binding or functional measures of potency; a KI or IC50 value. The potential toxicity
of a molecule can be measured in
terms of a potency at an unrelated or
off-target modulation of which could lead
to safety risks. For example, the popular
antibiotic azithromycin, which is designed against
a microbial target, also inhibits the human
cardiac IKR channel, which can lead to
life-threatening arrhythmias. The full difference in potencies between the microbial target, the denominator, and
human IKR; the numerator, is one way of quantifying
the safety margin or therapeutic index
for this compound, particularly at the stages when only in vitro data
are available. Compounds with a high
TI are considered safer than those with
lower TI values. It is important to
know what factors are being considered
when calculating a safety margin or TI because
not all toxicities are equal and measures of pharmacology
or efficacy can vary. For example, is the
safety margin based on adverse effects on the
gastrointestinal tract such as diarrhea or vomiting, or is it due to
adverse effects on the heart, such as arrhythmia? As a drug-hunting
program progresses, candidate molecules will
eventually emerge for which efficacy and toxicity testing will involve studies in animals. It is possible to describe
systemic exposure in animals purely based on plasma
or blood concentration. Exposure may be
related through C max; the peak concentration
of the drug. Or the more common
approach is to describe in vivo exposure
through integration of the CP time curve for an
area under curve AUC measure. The therapeutic index at this stage will be
calculated using the ratio of two values which differ from the earlier
in vitro example. In this case, the denominator
is the minimal exposure predicted to achieve the desired therapeutic
endpoint in humans. The other value, the numerator, is the highest exposure in animals that is deemed
to be safe called the no observed adverse
effect level or NOAEL. While a numeric TI value
can give the impression of a clear metric for
comparison of two molecules, TI value should be critically analyzed
and clearly defined. One key factor is correct identification of a
compound's adverse effects. Adverse effects can vary from one animal species to another. Toxicologists will need to consider whether
an observed risk will likely be relevant if the compound enters
clinical trials. Additionally, adverse
effects must be weighed relative to the
compound's indication. Drowsiness may be a problem
for an allergy medication, but much less relevant
for a life-saving drug. In summary, a molecule
safety can be determined by quantifying
its therapeutic index, which compares its efficacious
concentration dose or exposure to those
that lead to toxicity. Therapeutic index
is one tool which informs the drug-hunting
team of the relative risks versus benefits of a
molecule and helps guide selection of a drug candidate
to advance into the clinic